机译:基于结构的2,4-二氨基嘧啶衍生物的设计,其含有吡咯基作为ALK和ROS1抑制剂
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Dept Pharmacol Shenyang 110016 Peoples R China;
Shenyang Pharmaceut Univ Minist Educ Key Lab Struct Based Drug Design &
Discovery Shenyang 110016 Peoples R China;
机译:基于结构的2,4-二氨基嘧啶衍生物的设计,其含有吡咯基作为ALK和ROS1抑制剂
机译:轴承熔融三环环部分的新型2,4-二氨基吡啶胺用于促进淋巴瘤激酶(ALK)抑制剂
机译:新型的2,4-二氨基嘧啶类双环氨基苯并ze庚因类化合物用于间变性淋巴瘤激酶(ALK)抑制剂的合成和评价
机译:二硫脲二聚胺衍生物的能力抑制卵巢,骨,结肠,肺和乳腺癌细胞的能力
机译:药物化学中基于结构的药物设计:I.跨病变合成抑制剂的开发II。磺酰哌嗪衍生物对LpxH的抑制作用及其合成及生物学评价
机译:PF-06463922一种ALK / ROS1抑制剂在临床前模型中克服了对第一代和第二代ALK抑制剂的耐药性
机译:Repotrectinib(TPX-0005)是下一代ROS1 / TRK / ALK抑制剂,其效果抑制ROS1 / TRK /烷烃溶剂 - 前突变